Education
About Us
Working with TipRanks
Follow Us
Sera Prognostics (SERA)
NASDAQ:SERA
Top Page
Sera Prognostics
(NASDAQ:SERA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$3.50
▲(5.42% Upside)
Sera Prognostics faces significant financial challenges with declining revenues and substantial losses, heavily impacting its overall score. However, positive technical indicators and strategic progress in Medicaid pilot programs provide some optimism. The acceptance of the PRIME study for publication further supports the company's strategic direction, but valuation concerns remain due to ongoing losses.
Sera Prognostics (SERA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$137.01M
Dividend YieldN/A
Average Volume (3M)40.22K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth1.06%
EPS Growth22.41%
CountryUS
Employees63
SectorN/A
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.16
Shares Outstanding37,627,033
10 Day Avg. Volume55,279
30 Day Avg. Volume40,220
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)5.65
Price to Sales (P/S)3505.16
P/FCF Ratio-18.95
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue1.17K
Enterprise Value/Gross Profit-1.88K
Enterprise Value/Ebitda-3.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sera Prognostics Business Overview & Revenue Model
Company DescriptionSera Prognostics, Inc. is a biotechnology company specializing in maternal-fetal health diagnostics. The company focuses on the development and commercialization of innovative blood tests designed to predict the risk of adverse pregnancy outcomes, such as preterm birth and other complications. Its flagship product, the SeraTest, leverages advanced proteomics to provide healthcare providers with actionable insights for better management of pregnancies, ultimately aiming to improve maternal and infant health outcomes.
How the Company Makes MoneySera Prognostics generates revenue primarily through the sale of its diagnostic tests, including the SeraTest, to healthcare providers, hospitals, and laboratories. The company operates on a fee-for-service model, where it charges for each test performed. Additionally, Sera may engage in partnerships with healthcare organizations and pharmaceutical companies for research collaborations and the development of new tests, which can provide additional revenue streams. Insurance reimbursements also play a significant role in the company's revenue, as many diagnostic tests are covered by health insurance plans, facilitating broader adoption of their services. Furthermore, ongoing investments in R&D to expand their product offerings can lead to new revenue opportunities in the future.
Sera Prognostics Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 25, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant strategic progress with Medicaid pilot programs and leadership appointments, but financial metrics such as revenue decline and increased operating expenses present ongoing challenges.Q3-2025 Updates
Positive Updates
Geographically Focused Commercial Strategy
The company is advancing its geographically focused strategy to achieve payer coverage and physician education, with significant progress in Medicaid plan pilot programs in Nevada and discussions in 13 states.
Leadership Appointments
High-impact leadership appointments include Dr. Tiffany Inglis as Chief Medical Officer and Marisol Urbano as Head of Commercial Operations, enhancing the company's strategic direction and commercial operations.
First Medicaid Pilot Launch
The inaugural Medicaid pilot in Nevada is actively enrolling patients, marking a significant step in the company's commercialization strategy.
Negative Updates
Decline in Quarterly Revenue
Net revenue for the third quarter was $16,000, a decrease from $29,000 in the same period last year.
Operating Expenses Increase
Total operating expenses for the quarter were $9.0 million, compared to $8.9 million in the third quarter of 2024, with selling, general, and administrative expenses increasing from $5.4 million to $5.7 million.
Continued Net Loss
The company reported a net loss of $7.8 million for the quarter, slightly down from $7.9 million in the third quarter of 2024, but still indicating financial challenges.
Company Guidance
During the Sera Prognostics conference call to review third-quarter fiscal year 2025 results, the company highlighted several key metrics and strategic initiatives. Net revenue for the quarter was reported at $16,000, a decrease from $29,000 in the same period last year, attributed to the transition towards the commercialization of the PreTRM Test. The company recorded total operating expenses of $9.0 million, with research and development expenses decreasing to $3.3 million and selling, general, and administrative expenses rising to $5.7 million. Sera Prognostics emphasized progress in its Medicaid pilot programs, particularly in Nevada, and is engaging with 10 payers across 13 states, covering approximately 33% of U.S. births and 35% of Medicaid births annually. The company also reported cash and cash equivalents of $102.4 million as of September 30, 2025, and highlighted its strategic focus on achieving payer coverage and physician adoption. Looking ahead, Sera Prognostics remains on track to publish the full results of its PRIME study by the end of the year and is preparing for broader commercialization efforts, including expanding its sales force in target states.Sera Prognostics Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
30
Negative
Cash Flow
25
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Sera Prognostics Technical Analysis
Positive
3.32
Price Trends
3.22
Positive
3.06
Positive
2.94
Positive
Market Momentum
0.11
Negative
59.68
Neutral
81.58
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SERA, the sentiment is Positive. The current price of 3.32 is above the 20-day moving average (MA) of 3.30, above the 50-day MA of 3.22, and above the 200-day MA of 2.94, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 59.68 is Neutral, neither overbought nor oversold. The STOCH value of 81.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SERA.
Sera Prognostics Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
57 Neutral | $233.64M | -13.50 | -19.87% | ― | 5.44% | 72.17% | |
52 Neutral | $137.01M | -4.61 | -47.69% | ― | 1.06% | 22.41% | |
51 Neutral | $53.22M | -1.25 | -302.55% | ― | 22.29% | 31.93% | |
51 Neutral | $246.57M | -4.79 | -23.93% | ― | 159.45% | 8.59% | |
48 Neutral | $340.20M | -2.27 | -113.23% | ― | -41.87% | -165.76% | |
42 Neutral | $31.44M | -1.13 | ― | ― | 14.48% | 36.83% |
* Sector Average
SERA
Sera Prognostics
3.55
-5.05
-58.72%
VNRX
VolitionRX
0.26
-0.35
-57.38%
ACRS
Aclaris Therapeutics
3.14
0.25
8.65%
BNR
Burning Rock Biotech
21.70
15.20
233.85%
BDSX
Biodesix
6.69
-22.71
-77.24%
PRE
Prenetics Group
17.48
11.83
209.38%
Sera Prognostics Corporate Events
Business Operations and Strategy
Sera Prognostics’ PRIME Study Accepted for Publication
Positive
Nov 24, 2025
On November 24, 2025, Sera Prognostics announced that the findings of its PRIME study, one of the largest studies on preterm birth, were accepted for publication in a peer-reviewed journal. This development highlights the company’s commitment to advancing maternal and neonatal health through innovative research, potentially enhancing its industry positioning and providing significant insights for stakeholders.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.